{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T05:33:03Z","timestamp":1792128783252,"version":"4.4.0"},"reference-count":145,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.blre.2023.101117","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T12:28:19Z","timestamp":1690288099000},"page":"101117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment"],"prefix":"10.1016","volume":"62","author":[{"given":"Christina","family":"Darwish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.blre.2023.101117_bb0005","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.seminhematol.2015.04.002","article-title":"Core binding factor AML: new prognostic categories and therapeutic opportunities","volume":"52","author":"Chandrima Sinha","year":"2015","journal-title":"Semin Hematol"},{"issue":"20","key":"10.1016\/j.blre.2023.101117_bb0010","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101117_bb0015","article-title":"Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications","volume":"2011","author":"Reikvam","year":"2011","journal-title":"J Biomed Biotechnol"},{"issue":"4","key":"10.1016\/j.blre.2023.101117_bb0020","doi-asserted-by":"crossref","first-page":"E273","DOI":"10.1002\/ajh.24289","article-title":"Acute myeloid leukemia with inv(16)(p13.1q22), abnormal eosinophils, and absence of peripheral blood and bone marrow blasts","volume":"91","author":"Mangaru","year":"2016","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.blre.2023.101117_bb0025","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/ajh.23555","article-title":"The peripheral blood features of acute myeloid leukemia with inv(16)(p13.1q22)","volume":"88","author":"Sreedhara","year":"2013","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.blre.2023.101117_bb0030","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.blre.2023.101117_bb0035","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00503-6","article-title":"Core binding factor acute myelogenous leukemia-2021 treatment algorithm","volume":"11","author":"Borthakur","year":"2021","journal-title":"Blood Cancer J"},{"issue":"13","key":"10.1016\/j.blre.2023.101117_bb0040","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1182\/blood-2002-03-0772","article-title":"Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from cancer and leukemia group B (CALGB 8461)","volume":"100","author":"Byrd","year":"2002","journal-title":"Blood."},{"issue":"18","key":"10.1016\/j.blre.2023.101117_bb0045","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.2004.03.012","article-title":"Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German acute myeloid leukemia intergroup","volume":"22","author":"Schlenk","year":"2004","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.blre.2023.101117_bb0050","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.leukres.2014.04.001","article-title":"Population-based disparities in survival among patients with Core-binding factor acute myeloid leukemia: a SEER database analysis","volume":"38","author":"Brunner","year":"2014","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.blre.2023.101117_bb0055","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2006.06276.x","article-title":"The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations","volume":"135","author":"Appelbaum","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101117_bb0060","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/978-981-10-3233-2_12","article-title":"Clinical relevance of RUNX1 and CBFC alterations in acute Myelokd leukemia and other hematological disorders","author":"Metzeler","year":"2017","journal-title":"Adv Exp Med Biol"},{"issue":"24","key":"10.1016\/j.blre.2023.101117_bb0065","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1200\/JCO.2005.15.610","article-title":"Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a cancer and leukemia group B study","volume":"23","author":"Marcucci","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2023.101117_bb0070","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1309\/EM7KCQR4GLMHRCX4","article-title":"Prognostic impact of acute myeloid leukemia classification: importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival","volume":"119","author":"Arber","year":"2003","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"10.1016\/j.blre.2023.101117_bb0075","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/sj.leu.2404055","article-title":"Population-based demographic study of karyotypes in 1709 patients with adult acute myeloid leukemia","volume":"20","author":"Sanderson","year":"2006","journal-title":"Leukemia."},{"issue":"10","key":"10.1016\/j.blre.2023.101117_bb0080","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1038\/leu.2009.107","article-title":"Cytogenetic profile of de novo acute myeloid leukemia: a study based on 1432 patients in a single institution of China","volume":"23","author":"Cheng","year":"2009","journal-title":"Leukemia."},{"issue":"38","key":"10.1016\/j.blre.2023.101117_bb0085","doi-asserted-by":"crossref","first-page":"5665","DOI":"10.1038\/s41388-021-01952-w","article-title":"AML1\/ETO and its function as a regulator of gene transcription via epigenetic mechanisms","volume":"40","author":"Rejeski","year":"2021","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.blre.2023.101117_bb0090","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1242\/dev.01824","article-title":"The t(8;21) translocation converts AML1 into a constitutive transcriptional repressor","volume":"132","author":"Wildonger","year":"2005","journal-title":"Development."},{"key":"10.1016\/j.blre.2023.101117_bb0095","series-title":"AML1\/ETO \u2013 induced survivin expression inhibits transcriptional regulation of myeloid differentiation","first-page":"1449","author":"Balkhi","year":"2008"},{"issue":"21","key":"10.1016\/j.blre.2023.101117_bb0100","doi-asserted-by":"crossref","first-page":"8249","DOI":"10.1158\/0008-5472.CAN-09-1567","article-title":"Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a miR-24\/MKP-7\/MAPK network","volume":"69","author":"Zaidi","year":"2009","journal-title":"Cancer Res"},{"issue":"28","key":"10.1016\/j.blre.2023.101117_bb0105","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1038\/sj.onc.1209431","article-title":"Decreased intranuclear mobility of acute myeloid leukemia 1-containing fusion proteins is accompanied by reduced mobility and compartmentalization of core binding factor \u03b2","volume":"25","author":"Qiu","year":"2006","journal-title":"Oncogene."},{"issue":"19","key":"10.1016\/j.blre.2023.101117_bb0110","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood.2020009933","article-title":"Emerging therapies for inv(16) AML","volume":"137","author":"Surapally","year":"2021","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2023.101117_bb0115","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/00062752-200107000-00004","article-title":"Function of the inv(16) fusion gene CBFB-MYH11","volume":"8","author":"Kundu","year":"2001","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"10.1016\/j.blre.2023.101117_bb0120","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1365-2141.2004.05236.x","article-title":"Pathogenesis of acute myeloid leukaemia and inv(16)(p13;q22): a paradigm for understanding leukaemogenesis?","volume":"128","author":"Reilly","year":"2005","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2023.101117_bb0125","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/leu.2013.257","article-title":"CBFB-MYH11\/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia","volume":"28","author":"Mandoli","year":"2014","journal-title":"Leukemia."},{"issue":"24","key":"10.1016\/j.blre.2023.101117_bb0130","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1182\/bloodadvances.2020002673","article-title":"Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication","volume":"4","author":"Jahn","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.blre.2023.101117_bb0135","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood-2012-05-431486","article-title":"Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AMLStudy group (AMLSG)","volume":"121","author":"Paschka","year":"2013","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.blre.2023.101117_bb0140","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1182\/bloodadvances.2020003605","article-title":"Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)","volume":"5","author":"Han","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.blre.2023.101117_bb0145","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1053\/j.seminoncol.2008.04.011","article-title":"Core binding factor acute myeloid leukemia","volume":"35","author":"Paschka","year":"2008","journal-title":"Semin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2023.101117_bb0150","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1080\/10428194.2019.1709836","article-title":"Loss of X chromosome predicts favorable prognosis in female patients with t(8;21) acute myeloid leukemia","volume":"61","author":"Chen","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.blre.2023.101117_bb0155","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1080\/10428194.2019.1683734","article-title":"Loss of the Y chromosome predicts a high relapse risk in younger adult male patients with t(8;21) acute myeloid leukemia on high-dose cytarabine consolidation therapy: a retrospective multicenter study","volume":"61","author":"Zhou","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.blre.2023.101117_bb0160","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1182\/blood-2005-09-3640","article-title":"Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study","volume":"107","author":"Cairoli","year":"2006","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2023.101117_bb0165","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11899-009-0011-8","article-title":"Clinical implications of c-Kit mutations in acute myelogenous leukemia","volume":"4","author":"Malaise","year":"2009","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"10.1016\/j.blre.2023.101117_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.hemonc.2016.08.005","article-title":"Prognostic importance of C-KIT mutations in core binding factor acute myeloid leukemia: a systematic review","volume":"10","author":"Ayatollahi","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther [Internet]"},{"issue":"12","key":"10.1016\/j.blre.2023.101117_bb0175","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/ng.3709","article-title":"The genomic landscape of core-binding factor acute myeloid leukemias","volume":"48","author":"Faber","year":"2016","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.blre.2023.101117_bb0180","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2023.101117_bb0185","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3324\/haematol.2021.278645","article-title":"Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study","volume":"107","author":"Kayser","year":"2022","journal-title":"Haematologica."},{"issue":"11","key":"10.1016\/j.blre.2023.101117_bb0190","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1182\/blood.V104.11.2022.2022","article-title":"Incidence and prognosis of RTKs and RAS mutations in CBF AML. A retrospective study of French adult ALFA and pediatric LAME trials","volume":"104","author":"Boissel","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2023.101117_bb0195","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/sj.leu.2404188","article-title":"Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)","volume":"20","author":"Boissel","year":"2006","journal-title":"Leukemia."},{"issue":"39","key":"10.1016\/j.blre.2023.101117_bb0200","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/jncimonographs\/lgn003","article-title":"Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia","volume":"1228","author":"Mr\u00f3zek","year":"2008","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"23","key":"10.1016\/j.blre.2023.101117_bb0205","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.blre.2023.101117_bb0210","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1002\/cncr.24367","article-title":"Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia","volume":"115","author":"Borthakur","year":"2009","journal-title":"Cancer."},{"issue":"7","key":"10.1016\/j.blre.2023.101117_bb0215","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/ajh.25814","article-title":"Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: a bone marrow pathology group study","volume":"95","author":"Rogers","year":"2020","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.blre.2023.101117_bb0220","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.leukres.2012.09.008","article-title":"Therapy-related acute myeloid leukemia with favorable cytogenetics: still favorable?","volume":"36","author":"Aldoss","year":"2012","journal-title":"Leuk Res [Internet]"},{"key":"10.1016\/j.blre.2023.101117_bb0225","author":"National Comprehensive Cancer Network"},{"issue":"1","key":"10.1016\/j.blre.2023.101117_bb0230","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.1993.11.1.116","article-title":"Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy","volume":"11","author":"Gandhi","year":"1993","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.blre.2023.101117_bb0235","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1002\/cncr.23927","article-title":"Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival","volume":"113","author":"Borthakur","year":"2008","journal-title":"Cancer."},{"issue":"June","key":"10.1016\/j.blre.2023.101117_bb0240","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/ajh.26700","article-title":"Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia","author":"Borthakur","year":"2022","journal-title":"M Am J Hematol"},{"issue":"4","key":"10.1016\/j.blre.2023.101117_bb0245","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.blre.2023.101117_bb0250","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial","volume":"31","author":"Burnett","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2023.101117_bb0255","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1365-2141.2005.05745.x","article-title":"Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients","volume":"131","author":"Russo","year":"2005","journal-title":"Br J Haematol"},{"issue":"Nov","key":"10.1016\/j.blre.2023.101117_bb0260","first-page":"526","article-title":"FLAG-Ida combined with gemtuzumab ozogamicin (go) improves event free survival in younger patients with newly diagnosed acute myeloid leukaemia (aml) and shows an overall survival benefit in NPM1 and FLT3 mutated Subgroups","volume":"140","author":"Russell","year":"2022","journal-title":"Results from the UK NCRI AML19"},{"issue":"7","key":"10.1016\/j.blre.2023.101117_bb0265","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1517\/14728222.2014.909413","article-title":"The role of CD33 as therapeutic target in acute myeloid leukemia","volume":"18","author":"Walter","year":"2014","journal-title":"Expert Opin Ther Targets"},{"issue":"6","key":"10.1016\/j.blre.2023.101117_bb0270","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.blre.2023.101117_bb0275","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.blre.2023.101117_bb0280","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3324\/haematol.2016.141937","article-title":"Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg\/m2 with 6 mg\/m2 in the NCRI AML17 trial","volume":"101","author":"Burnett","year":"2016","journal-title":"Haematologica."},{"issue":"9","key":"10.1016\/j.blre.2023.101117_bb0285","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9825","key":"10.1016\/j.blre.2023.101117_bb0290","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet."},{"issue":"21","key":"10.1016\/j.blre.2023.101117_bb0295","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1182\/blood.V118.21.79.79","article-title":"Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study","volume":"118","author":"Delaunay","year":"2011","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.blre.2023.101117_bb0300","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2012.42.2964","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia","volume":"30","author":"Burnett","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.blre.2023.101117_bb0305","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1634\/theoncologist.2017-0604","article-title":"FDA approval summary: mylotarg for treatment of patients with relapsed or refractory CD33-positive acute myeloid leukemia","volume":"23","author":"Norsworthy","year":"2018","journal-title":"Oncologist."},{"issue":"22","key":"10.1016\/j.blre.2023.101117_bb0310","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/blood-2017-09-797712","article-title":"Gemtuzumab ozogamicin for acute myeloid leukemia","volume":"130","author":"Appelbaum","year":"2017","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.blre.2023.101117_bb0315","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/ajh.23795","article-title":"Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia","volume":"89","author":"Borthakur","year":"2014","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.blre.2023.101117_bb0320","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood.2019003471","article-title":"Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia","volume":"135","author":"Fournier","year":"2020","journal-title":"Blood."},{"issue":"16","key":"10.1016\/j.blre.2023.101117_bb0325","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1158\/1078-0432.CCR-18-1897","article-title":"Functional properties of KIT mutations are associated with differential clinical outcomes and response to targeted therapeutics in CBF acute myeloid leukemia","volume":"25","author":"Tarlock","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.blre.2023.101117_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00975-2","article-title":"Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia","volume":"13","author":"Cortes","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.blre.2023.101117_bb0335","article-title":"Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haematopoietic stem cell transplantation","volume":"2015","author":"Cheuk","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"28","key":"10.1016\/j.blre.2023.101117_bb0340","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.1200\/JCO.2008.21.0674","article-title":"Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup","volume":"27","author":"Pr\u00e9bet","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.blre.2023.101117_bb0345","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.blre.2023.101117_bb0350","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.blre.2023.101117_bb0355","doi-asserted-by":"crossref","first-page":"E59","DOI":"10.1002\/ajh.26057","article-title":"Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia","volume":"96","author":"Arslan","year":"2021","journal-title":"Am J Hematol"},{"issue":"18","key":"10.1016\/j.blre.2023.101117_bb0360","first-page":"4173","article-title":"Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype","volume":"58","author":"Bloomfield","year":"1998","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.blre.2023.101117_bb0365","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1200\/JCO.1999.17.12.3767","article-title":"Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered","volume":"17","author":"Byrd","year":"1999","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2023.101117_bb0370","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1200\/JCO.2004.07.012","article-title":"Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461","volume":"22","author":"Byrd","year":"2004","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.blre.2023.101117_bb0375","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2010-07-295279","article-title":"Arandomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSGAML201 study","volume":"117","author":"Miyawaki","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101117_bb0380","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199410063311402","article-title":"Intensive postremission chemotherapy in adults with AML","author":"Mayer","year":"1994","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.blre.2023.101117_bb0385","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood-2004-01-0326","article-title":"A randomized trial of high- versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine","volume":"105","author":"Bradstock","year":"2005","journal-title":"Blood [Internet]"},{"key":"10.1016\/j.blre.2023.101117_bb0390","article-title":"Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry","author":"Hanoun","year":"2022","journal-title":"J Cancer Res Clin Oncol [Internet]"},{"key":"10.1016\/j.blre.2023.101117_bb0700","first-page":"464","article-title":"Two cycles of consolidation chemotherapy are associated with similar clinical outcomes to three cycles in AML patients with favorable risk cytogenetics","volume":"130","author":"Sawler","year":"2017","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2023.101117_bb0705","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/ejh.13089","article-title":"Prognostic markers in core-binding factor AML and improved survival with multiple consolidation cycles of intermediate\u2212\/high-dose cytarabine","volume":"101","author":"Prabahran","year":"2018","journal-title":"Eur J Haematol"},{"issue":"August","key":"10.1016\/j.blre.2023.101117_bb0395","first-page":"1","article-title":"Clinical benefits and safety of gemtuzumab ozogamicin in treating acute myeloid leukemia in various subgroups: an updated systematic review, meta-analysis, and network Meta-analysis","volume":"12","author":"Xu","year":"2021","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.blre.2023.101117_bb0400","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","article-title":"Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation","volume":"102","author":"Wadleigh","year":"2003","journal-title":"Blood [Internet]"},{"issue":"7","key":"10.1016\/j.blre.2023.101117_bb0405","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/s41375-018-0129-6","article-title":"Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial","volume":"32","author":"Paschka","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.blre.2023.101117_bb0410","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/bloodadvances.2019000492","article-title":"Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801","volume":"4","author":"Marcucci","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.blre.2023.101117_bb0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-020-00196-2","article-title":"Advances in targeted therapy for acute myeloid leukemia","volume":"8","author":"Yu","year":"2020","journal-title":"Biomark Res"},{"issue":"May","key":"10.1016\/j.blre.2023.101117_bb0420","article-title":"Immunotherapy in acute myeloid leukemia: where we stand","volume":"11","author":"Isidori","year":"2021","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.blre.2023.101117_bb0425","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1080\/10428194.2017.1410882","article-title":"A tool compound targeting the core binding factor runt domain to disrupt binding to CBF\u03b2","volume":"59","author":"Oo","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.blre.2023.101117_bb0430","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1182\/blood-2014-01-549212","article-title":"Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML intergroup","volume":"124","author":"Hospital","year":"2014","journal-title":"Blood."},{"issue":"14","key":"10.1016\/j.blre.2023.101117_bb0435","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1182\/blood-2012-06-435669","article-title":"Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial","volume":"120","author":"Liu Yin","year":"2012","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.blre.2023.101117_bb0440","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1182\/blood.V99.10.3517","article-title":"A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML intergroup","volume":"99","author":"Nguyen","year":"2002","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2023.101117_bb0450","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bbmt.2007.10.006","article-title":"HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML intergroup and CIBMTR","volume":"14","author":"Schlenk","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.blre.2023.101117_bb0455","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1182\/blood-2008-03-145862","article-title":"Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: T(8;21) and inv(16) represent different clinical outcomes","volume":"113","author":"Kuwatsuka","year":"2009","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2023.101117_bb0460","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.bbmt.2017.12.796","article-title":"Comparison of autologous stem cell transplantation versus haploidentical donor stem cell transplantation for favorable- and intermediate-risk acute myeloid leukemia patients in first complete remission","volume":"24","author":"Chen","year":"2018","journal-title":"Biol Blood Marrow Transplant [Internet]"},{"issue":"4","key":"10.1016\/j.blre.2023.101117_bb0465","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s12185-022-03370-4","article-title":"Autologous stem cell transplantation in favorable-risk acute myeloid leukemia: single-center experience and current challenges","volume":"116","author":"Capria","year":"2022","journal-title":"Int J Hematol"},{"issue":"19","key":"10.1016\/j.blre.2023.101117_bb0470","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1200\/JCO.2007.15.3106","article-title":"Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood an","volume":"26","author":"Gorin","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2023.101117_bb0475","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000366261","article-title":"Equivalent outcome of autologous stem cell transplantation and reduced intensity conditioning stem cell transplantation in acute myeloid leukemia patients with t(8;21)","volume":"133","author":"Eom","year":"2015","journal-title":"Acta Haematol"},{"issue":"2","key":"10.1016\/j.blre.2023.101117_bb0480","doi-asserted-by":"crossref","first-page":"173.e1","DOI":"10.1016\/j.jtct.2020.10.010","article-title":"Allogeneic hematopoietic stem cell transplantation improved survival for adult Core binding factor acute myelogenous leukemia patients with intermediate- and adverse-risk genetics in the 2017 European LeukemiaNet","volume":"27","author":"Wang","year":"2021","journal-title":"Transplant Cell Ther [Internet]"},{"issue":"12","key":"10.1016\/j.blre.2023.101117_bb0485","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1038\/bmt.2014.180","article-title":"Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation","volume":"49","author":"Yoon","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.blre.2023.101117_bb0710","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.bbmt.2008.08.012","article-title":"Autologous stem cell transplantation with PCR-negative graft would be associated with a favorable outcome in core-binding factor acute myeloid leukemia","volume":"14","author":"Nakasone","year":"2008","journal-title":"Biol Blood Marrow Transplant [Internet]"},{"issue":"10","key":"10.1016\/j.blre.2023.101117_bb0715","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1080\/10428194.2019.1594214","article-title":"Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation","volume":"60","author":"Beyar-Katz","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.blre.2023.101117_bb0720","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1038\/s41409-019-0762-3","article-title":"Excellent outcome after consolidation with autologous transplantation in patients with core binding factor acute myeloid leukemia","volume":"55","author":"Sula","year":"2020","journal-title":"Bone Marrow Transplant [Internet]"},{"issue":"5","key":"10.1016\/j.blre.2023.101117_bb0725","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/hon.2806","article-title":"Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia","volume":"38","author":"Borlenghi","year":"2020","journal-title":"Hematol Oncol"},{"issue":"6","key":"10.1016\/j.blre.2023.101117_bb0730","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s12185-021-03099-6","article-title":"Autologous hematopoietic cell transplantation following high-dose cytarabine consolidation for core-binding factor-acute myeloid leukemia in first complete remission: a phase 2 prospective trial","volume":"113","author":"Choi","year":"2021","journal-title":"Int J Hematol"},{"issue":"26","key":"10.1016\/j.blre.2023.101117_bb0490","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.blre.2023.101117_bb0495","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ajh.26496","article-title":"Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia","volume":"97","author":"Senapati","year":"2022","journal-title":"Am J Hematol"},{"issue":"26","key":"10.1016\/j.blre.2023.101117_bb0500","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.2217\/fon-2022-0450","article-title":"Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia","volume":"18","author":"Ivanov","year":"2022","journal-title":"Future Oncol"},{"issue":"4","key":"10.1016\/j.blre.2023.101117_bb0505","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ajh.23655","article-title":"Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy","volume":"89","author":"Jabbour","year":"2014","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2023.101117_bb0510","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00606-8","article-title":"European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response","volume":"12","author":"Begna","year":"2022","journal-title":"Blood Cancer J"},{"issue":"23","key":"10.1016\/j.blre.2023.101117_bb0515","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","article-title":"Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure","volume":"28","author":"Duval","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2023.101117_bb0520","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.3324\/haematol.2019.222810","article-title":"Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the acute leukemia working party of the european society for blood and marrow transplantation","volume":"105","author":"Halaburda","year":"2020","journal-title":"Haematologica."},{"issue":"10","key":"10.1016\/j.blre.2023.101117_bb0525","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.2011.40.5977","article-title":"Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission","volume":"31","author":"Burnett","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2023.101117_bb0530","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-022-00654-0","article-title":"Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with \u201c7+3\u201d","volume":"12","author":"Begna","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.blre.2023.101117_bb0535","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.clml.2017.09.017","article-title":"Outcomes of patients with relapsed core binding factor-positive acute myeloid leukemia","volume":"18","author":"Khan","year":"2018","journal-title":"Clin Lymphoma, Myeloma Leuk [Internet]"},{"issue":"11","key":"10.1016\/j.blre.2023.101117_bb0540","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.3324\/haematol.2010.027516","article-title":"Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse","volume":"95","author":"Kurosawa","year":"2010","journal-title":"Haematologica."},{"issue":"5","key":"10.1016\/j.blre.2023.101117_bb0545","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/apm.12926","article-title":"Measurable residual disease testing for personalized treatment of acute myeloid leukemia","volume":"127","author":"Ehinger","year":"2019","journal-title":"Apmis."},{"issue":"1","key":"10.1016\/j.blre.2023.101117_bb0550","doi-asserted-by":"crossref","first-page":"E676","DOI":"10.1097\/HS9.0000000000000676","article-title":"Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia: experience of the European LeukemiaNet MRD working party","volume":"6","author":"Tettero","year":"2022","journal-title":"HemaSphere."},{"issue":"26","key":"10.1016\/j.blre.2023.101117_bb0555","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD working party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.blre.2023.101117_bb0560","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD working party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.blre.2023.101117_bb0565","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00277-021-04432-z","article-title":"Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center","volume":"100","author":"Duan","year":"2021","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.blre.2023.101117_bb0570","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jpm10040250","article-title":"Clinical outcomes based on measurable residual disease status in patients with core-binding factor acute myeloid leukemia: a systematic review and meta-analysis","volume":"10","author":"Rotchanapanya","year":"2020","journal-title":"J Pers Med"},{"issue":"1","key":"10.1016\/j.blre.2023.101117_bb0575","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/bloodadvances.2019000709","article-title":"Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11","volume":"4","author":"Ishikawa","year":"2020","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.blre.2023.101117_bb0580","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s00277-014-2107-z","article-title":"High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML)","volume":"93","author":"Wang","year":"2014","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.blre.2023.101117_bb0585","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/bjh.16745","article-title":"The loss or absence of minimal residual disease of <0\u00b71% at any time after two cycles of consolidation chemotherapy in CBFB\u2013MYH11-positive acute myeloid leukaemia indicates poor prognosis","volume":"192","author":"Duan","year":"2021","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2023.101117_bb0590","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/ejh.12130","article-title":"Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings and minimal residual disease","volume":"91","author":"Hoyos","year":"2013","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.blre.2023.101117_bb0595","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2012-10-462879","article-title":"Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia","volume":"121","author":"Jourdan","year":"2013","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.blre.2023.101117_bb0600","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3324\/haematol.2015.131946","article-title":"Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial","volume":"101","author":"Willekens","year":"2016","journal-title":"Haematologica."},{"issue":"6","key":"10.1016\/j.blre.2023.101117_bb0605","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ajcp\/aqw038","article-title":"Comparison of multiparameter flow cytometry Immunophenotypic analysis and quantitative RT-PCR for the detection of minimal residual disease of core binding factor acute myeloid leukemia","volume":"145","author":"Ouyang","year":"2016","journal-title":"Am J Clin Pathol"},{"issue":"20","key":"10.1016\/j.blre.2023.101117_bb0610","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1182\/blood-2012-11-468348","article-title":"MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial","volume":"121","author":"Zhu","year":"2013","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2023.101117_bb0615","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1080\/10428194.2020.1846736","article-title":"Allogeneic hematopoietic stem cell transplantation could improve survival for pure CBF-AML patients with minimal residual disease positive after the second consolidation","volume":"62","author":"Wang","year":"2021","journal-title":"Leuk Lymphoma [Internet]"},{"issue":"1","key":"10.1016\/j.blre.2023.101117_bb0620","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3324\/haematol.2019.235721","article-title":"Measurable residual disease monitoring provides insufficient lead-time to prevent morphological relapse in the majority of patients with core-binding factor acute myeloid leukemia","volume":"106","author":"Puckrin","year":"2021","journal-title":"Haematologica."},{"issue":"19","key":"10.1016\/j.blre.2023.101117_bb0625","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/blood.2019001425","article-title":"Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group","volume":"134","author":"R\u00fccker","year":"2019","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.blre.2023.101117_bb0630","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.blre.2023.101117_bb0635","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/ajh.24782","article-title":"Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia","volume":"92","author":"Ragon","year":"2017","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.blre.2023.101117_bb0640","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.2016.159343","article-title":"Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis","volume":"102","author":"Buckley","year":"2017","journal-title":"Haematologica."},{"issue":"16_suppl","key":"10.1016\/j.blre.2023.101117_bb0645","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1200\/JCO.2022.40.16_suppl.7006","article-title":"Pre-MEASURE: multicenter evaluation of the prognostic significance of measurable residual disease testing prior to allogeneic transplantation for adult patients with AML in first remission","volume":"40","author":"Hourigan","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.blre.2023.101117_bb0650","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1038\/s41409-021-01409-4","article-title":"Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission","volume":"56","author":"Konuma","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.blre.2023.101117_bb0655","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/cncr.32769","article-title":"Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes","volume":"126","author":"Yalniz","year":"2020","journal-title":"Cancer."},{"issue":"11","key":"10.1016\/j.blre.2023.101117_bb0660","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2023.101117_bb0665","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S2352-3026(18)30022-X","article-title":"Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase","volume":"5","author":"Fasslrinner","year":"2018","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.blre.2023.101117_bb0670","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S1470-2045(12)70349-2","article-title":"Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial","volume":"13","author":"Bornh\u00e4user","year":"2012","journal-title":"Lancet Oncol [Internet]"},{"issue":"12","key":"10.1016\/j.blre.2023.101117_bb0675","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2023.101117_bb0680","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/bjh.14340","article-title":"Monitoring of post-transplant CBFB-MYH11 as minimal residual disease, rather than KIT mutations, can predict relapse after allogeneic haematopoietic cell transplantation in adults with inv(16) acute myeloid leukaemia","volume":"180","author":"Tang","year":"2018","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.blre.2023.101117_bb0685","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2014-03-563403","article-title":"In adults with t(8;21)AML, posttransplant RUNX1\/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification","volume":"124","author":"Wang","year":"2014","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.blre.2023.101117_bb0690","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.clml.2021.05.016","article-title":"Acute myeloid leukemia: historical perspective and Progress in research and therapy over 5 decades","volume":"21","author":"Kantarjian","year":"2021","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"key":"10.1016\/j.blre.2023.101117_bb0695","series-title":"National Cancer Institute SEER*Stat software (seer.cancer.gov\/seerstat) version 22","author":"Surveillance Research Program","year":"2023"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:30:15Z","timestamp":1759437015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X23000784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":145,"alternative-id":["S0268960X23000784"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2023.101117","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2023.101117","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101117"}}